Abstract
The early growth response-1 (Egr-1) gene encodes a Cys2-His2-type zinc-finger transcription factor. A broad range of extra cellular stimuli are known to lead to its induction thus furthering growth, proliferation, differentiation or apoptosis. Accordingly, Egr-1 is involved in a variety of diseases such as atherosclerosis or cancer. Among other functional elements, five serum response elements (SRE) have been identified in the promoter region of Egr-1. The Rho/Rho-kinase pathway has been shown to regulate actin reorganization via LIM-kinase mediated cofilin phosphorylation. Recent studies revealed the actin binding striated muscle activator of Rho signaling (STARS) to promote translocation of myosin related transcription factors (MRTFs) into the nucleus leading to serum response factor (SRF) activation. The ternary complex factor (TCF) Elk-1 eventually bridges the gap between SRF mediated gene transcription and the Raf/MEK/ERK pathway. Furthermore, the Egr-1 promoter has two cAMP response elements (CREs), whose relevance for gene expression is still controversial. An Egr-1 binding site (EBS) is located on the Egr-1 promoter itself arguing for a negative feedback mechanism. The acquired knowledge on transcriptional regulation, however, is not entirely understood. In this review we highlight upstream and downstream signaling in vitro and in vivo associated with Egr-1.
Keywords: Egr-1, signal transduction cascades, serum response factor, Rho-kinase, ERK1/2
Current Signal Transduction Therapy
Title: Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Volume: 5 Issue: 2
Author(s): Judith-Irina Pagel and Elisabeth Deindl
Affiliation:
Keywords: Egr-1, signal transduction cascades, serum response factor, Rho-kinase, ERK1/2
Abstract: The early growth response-1 (Egr-1) gene encodes a Cys2-His2-type zinc-finger transcription factor. A broad range of extra cellular stimuli are known to lead to its induction thus furthering growth, proliferation, differentiation or apoptosis. Accordingly, Egr-1 is involved in a variety of diseases such as atherosclerosis or cancer. Among other functional elements, five serum response elements (SRE) have been identified in the promoter region of Egr-1. The Rho/Rho-kinase pathway has been shown to regulate actin reorganization via LIM-kinase mediated cofilin phosphorylation. Recent studies revealed the actin binding striated muscle activator of Rho signaling (STARS) to promote translocation of myosin related transcription factors (MRTFs) into the nucleus leading to serum response factor (SRF) activation. The ternary complex factor (TCF) Elk-1 eventually bridges the gap between SRF mediated gene transcription and the Raf/MEK/ERK pathway. Furthermore, the Egr-1 promoter has two cAMP response elements (CREs), whose relevance for gene expression is still controversial. An Egr-1 binding site (EBS) is located on the Egr-1 promoter itself arguing for a negative feedback mechanism. The acquired knowledge on transcriptional regulation, however, is not entirely understood. In this review we highlight upstream and downstream signaling in vitro and in vivo associated with Egr-1.
Export Options
About this article
Cite this article as:
Pagel Judith-Irina and Deindl Elisabeth, Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades, Current Signal Transduction Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157436210791112190
DOI https://dx.doi.org/10.2174/157436210791112190 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals Patent Selections
Recent Patents on Biotechnology Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology Perfusion MRI of Brain Neoplams
Current Medical Imaging Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Novel Approaches to Cancer Therapy Using Oncolytic Viruses
Current Molecular Medicine The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Xanthohumol: A Metabolite with Promising Anti-Neoplastic Potential
Anti-Cancer Agents in Medicinal Chemistry Equinatoxin II Potentiates Temozolomide- and Etoposide-Induced Glioblastoma Cell Death
Current Topics in Medicinal Chemistry